Thinking inside the box. To cope with an increasing disease burden, drug discovery needs biologically relevant and predictive testing systems

EMBO Reports

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Sundstrom, Lars E ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; SILDENAFIL; TGN 1412; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ARTHRITIS; ARTICLE; BRAIN DISEASE; CAREGIVER; CLINICAL TRIAL; CYSTIC FIBROSIS; DEMENTIA; DRUG INDUSTRY; DRUG SAFETY; EMBRYONIC STEM CELL; EMOTIONALITY; ERECTILE DYSFUNCTION; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMIA; LIFE EXPECTANCY; MEDICAL ETHICS; MEDICAL LITERATURE; MORALITY; MULTIPLE SCLEROSIS; MUSCULAR DYSTROPHY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SOCIOECONOMICS; STROKE;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 34548351274     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/sj.embor.7400939     Document Type: Article

References (24)

1. Alzheimer's Association (2006) Alzheimer's Disease Statistics. Chicago, IL, USA: Alzheimer's Association
2. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J (2005) Costs of disorders of the brain in Europe. Eur J Neurol 12: 1-27
3. Archibald K (2006) It's time to test the testers. The Guardian, 5 May. www.guardian.co.uk
4. British Broadcasting Corporation (2007) Hybrid embryo work 'under threat'. BBC News Online, 5 Jan
5. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22: 151-185
6. Doan TN, Eilertson CD, Rubenstein AL (2004) High-throughput target validation in model organisms. Drug Discov Today Targets 3: 191-197
7. Drews J (2000) Drug discovery: A historical perspective. Science 287: 1960-1964
8. Ghofrani HA, Osterloh IH, Grimminger F (2006) Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 5: 689-702
9. Giuliano KA, Johnston PA, Gough A, Taylor DL (2006) Systems cell biology based on high-content screening. Meth Enzymol 414: 601-619
10. Goodyear M (2006) Learning from the TGN1412 trial. BMJ 332: 677-678
11. Gorba T, Allsopp TE (2003) Pharmacological potential of embryonic stem cells. Pharmacol Res 47: 269-278
12. Harris G (2002) Why drug makers are failing in search for new blockbusters. Wall Street Journal, 18 Apr
13. Higgs G (2004) Molecular genetics: The Emperor's clothes of drug discovery? Drug Discov Today 9: 727-729
14. Lansbury PT (2004) Back to the future: The 'old-fashioned' way to new medications for neurodegeneration. Nat Med 10: S51-S57
15. Olesen J, Leonardi M (2003) The burden of brain diseases in Europe. Eur J Neurol 10: 471-477
16. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996
17. Pouton CW, Haynes JM (2005) Pharmaceutical applications of embryonic stem cells. Adv Drug Deliv Rev 57: 1918-1934
18. Sams-Dodd F (2006) Drug discovery: Selecting the optimal approach. Drug Discov Today 11: 465-472
19. Sciolino E (2006) Catholic clergy attack French telethon over stem cell aid. The New York Times, 8 Dec. www.nytimes.com
20. Sundstrom L, Morrison B 3rd, Bradley M, Pringle A (2005) Organotypic cultures as tools for functional screening in the CNS. Drug Discov Today 10: 993-1000
21. Wadman M (2006) Earlier drug tests on people could be unsafe, critics warn. Nat Med 12: 153
22. Walker MJ, Barrett T, Guppy LJ (2004) Functional pharmacology: The drug discovery bottleneck? Drug Discov Today Targets 3: 208-215
23. Warne P, Page C (2003) Is there a best strategy for drug discovery? Drug News Perspect 16: 177-182
24. Williams M (2004) A return to the fundamentals of drug discovery? Curr Opin Investig Drugs 5: 29-33